Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radiotherapy Combined With GDP (Gemcitabine, Cisplatin, Dexamethasone) Chemotherapy With or Without Chidamide in High-risk Early-stage Extranodal Nasal NK/T-cell Lymphoma

Next Previous
X
Search
Trial Profile

Radiotherapy Combined With GDP (Gemcitabine, Cisplatin, Dexamethasone) Chemotherapy With or Without Chidamide in High-risk Early-stage Extranodal Nasal NK/T-cell Lymphoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Dexamethasone (Primary) ; Gemcitabine (Primary) ; Tucidinostat (Primary)
  • Indications Extranodal NK-T-cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 15 Jul 2022 Status changed from recruiting to discontinued, according to the results published in the International Journal of Radiation Oncology, Biology, Physics.
    • 15 Jul 2022 According to the results published in the International Journal of Radiation Oncology, Biology, Physics, as no trend to meet the primary endpoint of the study was observed, the enrollment was terminated early considering the possible AEs associated with chidamide administration. Follow-up time was extended until June 2021.
    • 15 Jul 2022 Primary endpoint(Progression-free survival) has not been met, according to the results published in the International Journal of Radiation Oncology, Biology, Physics.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top